HSBC Holdings plc set a GBX 4,100 ($53.39) price objective on AstraZeneca plc (LON:AZN) in a research note released on Tuesday morning. The firm currently has a sell rating on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other research reports. Morgan Stanley reiterated an overweight rating and set a GBX 5,600 ($72.93) price target on shares of AstraZeneca plc in a research report on Friday, June 23rd. Deutsche Bank AG reissued a buy rating on shares of AstraZeneca plc in a research note on Monday, May 22nd. Shore Capital reaffirmed a sell rating on shares of AstraZeneca plc in a research report on Thursday, May 4th. Barclays PLC reaffirmed an overweight rating and set a GBX 6,000 ($78.14) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 5,500 ($71.62) target price on shares of AstraZeneca plc in a research report on Wednesday, June 14th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of GBX 4,932.67 ($64.24).

AstraZeneca plc (LON:AZN) traded down 1.27% during midday trading on Tuesday, hitting GBX 4506.00. The stock had a trading volume of 2,260,915 shares. The firm’s market cap is GBX 57.05 billion. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock has a 50-day moving average price of GBX 5,022.16 and a 200 day moving average price of GBX 4,861.45.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/09/hsbc-holdings-plc-analysts-give-astrazeneca-plc-azn-a-gbx-4100-price-target.html.

The company also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be issued a dividend of GBX 68.90 ($0.90) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.

In other news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.91) per share, for a total transaction of £1,704.30 ($2,219.43).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.